These data are supported by many recently published studies demonstrated that increased CD8+/FOXP3+ ratio in breast cancer patients could be used as a good prognostic marker following neoadjuvant chemotherapy, as well as for prolonged relapse-free survival and overall survival rates compared to those with decreased CD8+/FOXP3+ ratio [41,42]. The gene discussed is CD8A; the disease is breast carcinoma.